All In Biotech

Drug Trial Radar · NCT07934017

A Study of SL-325 in Participants With Hidradenitis Suppurativa

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SL-325 in Participants With Moderate to Severe Hidradenitis Suppurativa (RECEPTIVE-HS1)

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jan 2027

Primary completion

Feb 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Shattuck Labs, Inc.Industry
Sponsor type
Industry
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the efficacy of SL-325 in adult participants with Hidradenitis Suppurativa. The study consists of a screening period of up to 5 weeks, a 16-week primary treatment period, 36-week extension period, and a follow-up period of up to 12 weeks.

Conditions

  • Hidradenitis Suppurativa (HS)

Interventions

  • SL-325Drug

    SL-325 administered intravenously

  • PlaceboDrug

    Placebo administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants achieving HiSCR50Time frame: Week 16

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.